



Article Nucleophilic Functionalization of 2-R-3-Nitropyridines as a Versatile Approach to Novel Fluorescent Molecules

Vladislav V. Nikol'skiy, Mikhail E. Minyaev, Maxim A. Bastrakov 💿 and Alexey M. Starosotnikov *💿

* Correspondence: alexey41@list.ru

Abstract: A number of new 2-methyl- and 2-arylvinyl-3-nitropyridines were synthesized and their reactions with thiols were studied. It was found that $3-NO_2$ tends to be selectively substituted under the action of sulfur nucleophiles in the presence of another nucleofuge in position 5. Correlations between the substitution pattern and regioselectivity as well as photophysical properties were established. Some synthesized compounds possessed a large Stokes shift.

Keywords: nitro group; nitropyridines; bis-(het)aryl ethenes; nucleophilic substitution; thiols; UV–Vis spectroscopy

1. Introduction

Pyridine is an important heterocyclic motif and a part of various natural products. The pyridine ring system is incorporated into alkaloids, medicines (for example, omeprazole, lorlatinib, ivosidenib and many others), fungicides, herbicides and insecticides. Application of the pyridine derivatives as biologically active precursors and coordination complexes was reviewed recently [1]. Nitropyridines are of particular interest due to their biological significance [2–5]. In addition, some nitropyridines are considered to be promising energetic compounds [6–10] and efficient organic optical materials [11]. The introduction of the nitro group into the pyridine ring facilitates its functionalization in different ways. Recently, we investigated reactions of 3-R-5-nitropyridines with various types of nucleophiles [12]. It was found that in the case of anionic S-, N- and O-nucleophiles, the substitution of the non-activated nitro group occurred while carbon nucleophiles underwent dearomatization of the pyridine ring with the formation of 1,2- or 1,4-addition products. As a result, a number of novel or hardly accessible pyridines and their dihydro derivatives were synthesized [12].

In this work we report on the synthesis, reactivity and photophysical properties of 2-methyl- and 2-(2-arylvinyl)-3-nitropyridines, as shown in Figure 1. 2-Alkenylpyridines are widely employed as precursors to pharmaceuticals (vorapaxar, axitinib, nifurpirinol) and other biologically active compounds [13]. In addition, 2-(2-arylvinyl)pyridines were proven to be the fluorescent molecules, with the fluorescence quantum yield showing a large dependence on the acidity of media [14].







Citation: Nikol'skiy, V.V.; Minyaev, M.E.; Bastrakov, M.A.; Starosotnikov, A.M. Nucleophilic Functionalization of 2-R-3-Nitropyridines as a Versatile Approach to Novel Fluorescent Molecules. *Molecules* 2022, 27, 5692. https://doi.org/10.3390/ molecules27175692

Academic Editor: Antonio Massa

Received: 4 August 2022 Accepted: 31 August 2022 Published: 3 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

N.D. Zelinsky Institute of Organic Chemistry RAS, Leninsky Prosp. 47, 11991 Moscow, Russia

2. Results and Discussion

2-Methyl-3-nitropyridines **2a–c** were synthesized from the corresponding commercially available 2-chloro-3-nitropyridines **1a–c** by the reaction with diethyl malonate, followed by acidic hydrolysis/decarboxylation, as shown in Scheme 1. The oxidation of compounds **2b,c** with the hydrogen peroxide–urea complex gave *N*-oxides **3b,c** in moderate yields.



Scheme 1. Synthesis of 2-methyl-3-nitropyridines.

We examined 2-methylpyridines **2** and **3** in reactions with aldehydes under piperidine catalysis. Our attempts to isolate condensation products of compounds **2b**,**c** failed, whereas 2-methyl-3,5-dinitropyridine **2a** and *N*-oxides **3b**,**c** gave diarylethenes **4a**–**g** in high yields, as shown in Scheme 2. It should be noted that compound **2a** reacts several times faster than pyridine *N*-oxides **3b**,**c**, indicating that *para*-NO₂ is a more potent activating group for this reaction than the *N*-oxide moiety neighboring the 2-methyl group. The functional group tolerance, along with the relatively mild conditions and availability of aromatic aldehydes, makes this method a valid alternative for Pd-catalyzed coupling reactions [15–18]. Deoxygenation of pyridine *N*-oxides **4c**,**e**–**g** with PCl₃ allowed us to obtain four additional 2-ethenylpyridines **4h**–**k**, which were inaccessible via direct condensation of 2-methylpyridines **2b**,**c** with aldehydes, as shown in Scheme 2.



Scheme 2. Synthesis of 2-(2-arylvinyl)-3-nitropyridines.

In all cases, only *trans*-diarylethenes are formed, which was confirmed by NMR spectroscopy: coupling constants of 15–16 Hz were observed for proton signals of the double bonds. In addition, X-ray analysis for compounds **4a**,**i** was performed, undoubtedly proving our assumption, as shown in Figure 2.



Figure 2. X-ray crystal structures of compounds **4a** (**left**) and **4i** (**right**) with thermal ellipsoids at 50% probability level.

The possibility of the substitution of the non-activated nitro group in pyridines was studied recently by our group [12]. In 3-nitro-5-Cl(Br)-pyridines, 3-NO₂ was found to be more nucleofugal than halogen in position 5. The reactions of 2-methyl-3-nitropyridines **2** and **3** with thiols are summarized in Scheme 3 and Table 1. Upon heating the reactants in DMF in the presence of K_2CO_3 , the selective formation of 3-R²S-products **5** was observed in all cases; however, the reaction of **2a** with BnSH gave **5a** with a trace amount of the isomer **6a**.



Scheme 3. Reactions of 2-methyl-3-nitropyridines with thiols.

Substrate	R ¹	n	R ²	Product, Isolated Yield (%)
2a	NO ₂	0	PhCH ₂	5 a, 70
3b	Br	1	PhCH ₂	5b , 96
3b	Br	1	4-Cl-C ₆ H ₄	5 c, 95
2b	Br	0	PhCH ₂	5d , 65
2c	CF ₃	0	PhCH ₂	5e , 60
3c	CF ₃	1	PhCH ₂	5f , 52

Table 1. Reactions of 2-methyl-3-nitropyridines with thiols.

Interestingly, diarylethenes **4** react with thiols under the same mild conditions, but with lower selectivity. ¹H NMR spectra of the crude products generally contain an additional set of signals corresponding to the $5\text{-R}^2\text{S}$ -isomer, whereas the ratio of 5/6 varied from 2:1 to 20:1 depending on the substrate and thiol. Moreover, compounds **6g**,**h** were isolated and fully characterized, but in all other cases we were unable to isolate isomers **6**, as shown in Scheme **4** and Table **2**.



Scheme 4. Reactions of 2-(arylvinyl)-3-nitropyridines with thiols.

Substrate	R ¹	Ar	n	R ²	Ratio 5/6 ª	Product, Isolated Yield (%)
4a	NO ₂	4-Cl-C ₆ H ₄	0	PhCH ₂	3:1	5g , 56 6g , 18
4a	NO ₂	4-Cl-C ₆ H ₄	0	i-C ₄ H ₉	2:1	5h , 62 6h , 31
4a	NO ₂	4-Cl-C ₆ H ₄	0	2-furylmethyl	>20:1	5i , 56
4a	NO ₂	4-Cl-C ₆ H ₄	0	4-Cl-C ₆ H ₄	>20:1	5 j, 67
4b	NO ₂	4-Me ₂ N-C ₆ H ₄	0	4-Cl-C ₆ H ₄	>20:1	5k , 83
4b	NO ₂	4-Me ₂ N-C ₆ H ₄	0	i-C ₄ H ₉	8:1	51 , 84
4b	NO ₂	$4-Me_2N-C_6H_4$	0	PhCH ₂	10:1	5m , 88
4d	NO ₂	1-(4-fluorophenyl)pyrazol- 4-yl	0	PhCH ₂	10:1	5n , 89
4d	NO ₂	1-(4-fluorophenyl)pyrazol- 4-yl	0	4-Cl-C ₆ H ₄	>20:1	50 , 93
4j	Br	4-Cl-C ₆ H ₄	0	PhCH ₂	>20:1	5p , 60
4f	Br	4-Me ₂ N-C ₆ H ₄	1	PhCH ₂	>20:1	5q , 67

 Table 2. Reactions of 2-(arylvinyl)-3-nitropyridines with thiols.

^a Determined from ¹H NMR spectrum of crude product.

Structures of compounds **5** and **6** were confirmed by NMR, HRMS, X-ray and elemental analysis. ¹H-¹H NOESY spectra of compounds **5m** and **5q** revealed interactions of the spatially close protons of the double bond and benzyl substituent, as shown in Figure 3. The structures of **5h**,**l** were determined by the X-ray diffraction single-crystal method, as shown in Figure 4.

The above-mentioned results allow us to conclude that electron-releasing substituents in the aryl group and the bulky thiolate anion favor substitution at position 3: the best selectivity was observed for reactions of **4b** with α -toluene thiol, whereas **4a** with isobutyl mercaptan gave the lowest selectivity (2:1). Reactions with 4-chlorothiophenol afforded exclusively a 3-substituted product.



Figure 3. Cross-peaks observed in ¹H-¹H NOESY spectrum of compounds **5m** ($R^1 = NO_2$) and **5q** ($R^1 = Br$).



Figure 4. X-ray crystal structures of compounds **5h** (left) and **5l** (right) with thermal ellipsoids at 50% probability level.

Compounds with multiple conjugated double bonds, such as diarylethenes **4–6**, can be expected to have strong absorbance in the UV and visible region; therefore, the photophysical properties of some representative compounds with various substitution patterns were studied. Indeed, it was found that all recorded UV–Vis spectra in the MeCN solution have a strong and distinctive absorption band in the 326-509 nm region accompanied by one or more weaker and non-informative bands around 260-300 nm (Figure 5, Table 3). Notable exceptions are compounds **4a**,**i** with only one dominant absorption maximum and compound **4e** with a stronger shortwave band, which can be attributed to the *N*-oxide moiety.



Figure 5. UV–Vis spectra of selected synthesized compounds in MeCN (2 \times 10⁻⁵ M).

Table 3. Photoph	ysical prope	erties of some	synthesized	compounds.
------------------	--------------	----------------	-------------	------------

Compound	$\lambda_{max} \ nm$	$\epsilon_1 \ \mathrm{dm^3} \ \mathrm{mol^{-1}} \ \mathrm{cm^{-1}}$	$\lambda_{max} nm$	$\epsilon_2 \ \mathrm{dm^3 \ mol^{-1} \ cm^{-1}}$
4a	-	-	368	46,400
4b	302	13,500	509	42,800
4c	263	16,200	397	34,900
4e	267	28,700	332	24,700
4i	-	-	326	39,000
4k	266	14,600	429	32,800
5g	296	16,000	384	20,300

Compound	$\lambda_{max} \ nm$	$\epsilon_1 dm^3 mol^{-1} cm^{-1}$	$\lambda_{max} \ nm$	$\epsilon_2 \ \mathrm{dm^3} \ \mathrm{mol^{-1}} \ \mathrm{cm^{-1}}$
5m	305	13,600	476	31,400
5n	266	18,100	403	25,900
5p	302	25,200	344	19,000
6g	267	15,000	337	31,400

Table 3. Cont.

In the case of dinitro compounds **4a–c**, the electron-releasing Me₂N group in the phenyl ring leads to a considerable red shift of the absorption maximum (by 141 nm) with respect to the electron-withdrawing chlorine atom (compounds **4a** and **4b**, Figure 6). Compound **4b**, with a strong electron-releasing 4-dimethylaminophenyl group, absorbs light in the visible region, whereas compounds **4a** and **4c** have their absorption maxima at the border between the visible and UV regions. This can be explained by the difference in the degree of charge transfer along the conjugation chain between the strongly withdrawing nitropyridine ring and the second electron-donating ring through the double bond.



Figure 6. UV–Vis spectra of compounds **4a–c** in MeCN (2×10^{-5} M).

On the other hand, the replacement of 5-NO_2 with the CF₃ group in a pyridine cycle caused a 42 nm blue shift for compounds 4a/4i and an 80 nm shift for 4-dimethylaminophenyl derivatives 4b/4k, as well as a small decrease in molar absorptivity (Figure 7). It can be concluded that substituents at the double bond as well as in position 5 can be independently altered to predictably fine-tune absorption spectra of these compounds.

The study of isomeric substitution products of 3- and 5-NO₂ in compound **4a** revealed an important dependence, as shown in Figure 8. Substitution of the nitro group at position 5 gave compound **6g**, whose absorption spectrum generally resembles that of the parent compound and follows the same pattern described above for the 5-NO₂/5-CF₃ pair. On the other hand, substitution of the nitro group at position 3 gave compound **5g**, which is qualitatively different from both compounds. In this case, the absorption maximum shifts slightly towards the visible region, and the absorption spectrum itself acquires a more complex structure. From this we can conclude that the combination of 2-alkenyl and 3-alkylthio substituents leads to the appearance of a characteristic electronic structure. A similar pattern was observed for the substitution of 3-NO₂ in compound **4c**, but not for



compound **4b**, which can be explained by the predominance of a strong charge transfer over the finer electronic structure. It should be noted that the alkylthio substituent does not significantly affect the photophysical properties of the obtained compounds.

Figure 7. UV–Vis spectra of compounds **4***a*,**b**,**i**,**k** in MeCN (2 \times 10⁻⁵ M).



Figure 8. UV–Vis spectra of compounds **4a**, **5g**, **6g** in MeCN (2×10^{-5} M).

Compounds **5***g*,**n** showed fluorescence upon excitation by light with the wavelength equal to the λ_{max} in the visible region, as shown in Figures 9 and 10. Compound **5***g* has an emission maximum at 538 nm and a Stokes shift of 154 nm, whereas for compound **5***n*, these values are 571 nm and 168 nm, respectively. The large values of Stokes shifts (150–170 nm) almost completely eliminate the overlap between the absorption and emission regions. In addition, the properties of these fluorescent molecules can be tuned by changing the substituent at the double bond.



Figure 9. Normalized absorption and emission spectra of compounds 5g and 5n in MeCN.



Figure 10. Fluorescence of compounds **5g** and **5n** in solid state and in MeCN solution under 365 nm UV lamp.

3. Conclusions

In conclusion, a number of the previously unknown 2-methyl- and 2-arylvinyl-3nitropyridines were synthesized. Their reactions with *S*-nucleophiles proceeded under mild conditions and were found to be regioselective with a predominance of 3-NO₂ substitution; the influence of the substituents in positions 2 and 5 on the observed selectivity was revealed. The synthesized compounds showed promising tunable photophysical properties, such as large Stokes shifts. The reported synthetic approach can be considered as a convenient tool for rapid access to pyridine-based building blocks of various potential applications.

4. Materials and Methods

4.1. General Information

All chemicals were of commercial grade and used directly without purification. Melting points were measured on a Stuart SMP20 apparatus (Stuart (Bibby Scientific), UK). ¹H and ¹³C NMR spectra were recorded on a Bruker AM-300 (at 300.13 and 75.13 MHz, respectively, Bruker Biospin, Germany) or Bruker Avance DRX 500 (at 500 and 125 MHz, respectively, Bruker Biospin, Germany) in DMSO-d₆ or CDCl₃. *J* values are given in Hz. HRMS spectra were recorded on a Bruker micrOTOF II mass spectrometer using ESI. UV–Vis absorption spectra were recorded in MeCN (2×10^{-5} M) in standard $10 \times 10 \times 45$ mm quartz cuvettes on a Cary 60 UV–Vis spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). Fluorescence spectra were recorded in MeCN (2×10^{-6} M) in standard $10 \times 10 \times 45$ mm quartz cuvettes on a Cary Eclipse fluorescence spectrophotometer (Agilent Technologies). All reactions were monitored by TLC analysis using ALUGRAM SIL G/UV254 plates, which were visualized with UV light. Compounds **1a–c** were purchased from commercial suppliers. In some cases we were unable to record the ¹³C NMR spectra of products due to insufficient solubility in common organic solvents (compounds **4d**, **5**, **i**, **j**, **0** and **6j**).

4.2. General Procedure for the Synthesis of 2-Methyl-3-nitropyridines 2a-c

To a stirred suspension of NaH (60% in mineral oil, 0.80 g, 20 mmol) in anhydrous THF (30 mL), diethyl malonate (1.52 mL, 10 mmol) was added dropwise. The suspension was stirred for 15 min until hydrogen evolution ceased and a solution of the corresponding 2-chloropyridine **1** (10 mmol) in THF (20 mL) was added. The reaction mixture was stirred at r.t. (room temperature) for 6 h, poured in water (200 mL) and acidified with conc. HCl to pH 3. This was then extracted with CHCl₃, evaporated and 50% H₂SO₄ (30 mL) was added to the residue. The mixture was stirred for 6 h at 120 °C, cooled, neutralized with Na₂CO₃ to pH 8 and extracted with CHCl₃. The organic phase was dried over Na₂SO₄, evaporated and the residue was purified via column chromatography (SiO₂/CHCl₃).

2-*Methyl*-3,5-*dinitropyridin* (**2a**) [19], brown oil; yield 62%; ¹H NMR (300 MHz, CDCl₃): δ 9.55 (d, 1H, *J* = 2.1 Hz), 9.06 (d, 1H, *J* = 2.1 Hz), 3.03 (s, 3H).

5-*Bromo*-2-*methyl*-3-*nitropyridin* (**2b**) [20], yellowish oil; yield 90%; 1H NMR (300 MHz, CDCl₃): δ 8.80 (d, 1H, J = 2.1 Hz), 8.44 (d, 1H, J = 2.1 Hz), 2.84 (s, 3H).

2-*Methyl-3-nitro-5-trifluoromethylpyridine* (2c), yellowish oil; yield 81%; 1H NMR (300 MHz, CDCl₃): δ 9.00 (s, 1H), 8.54 (s, 1H), 2.97 (s, 3H).

4.3. General Procedure for the Oxidation of 2-Methyl-3-nitropyridines 2b,c

To a solution of the corresponding 2-methyl-3-nitropyridine **2** (10 mmol) in CH₂Cl₂ (30 mL), a freshly prepared complex urea/H₂O₂ (1.88 g, 20 mmol) was added. The resulting suspension was cooled to 0 °C and trifluoroacetic anhydride (5 mL, 36 mol) was added dropwise. The reaction mixture was stirred for 30 min at 0 °C and 4 h at r.t. A saturated aqueous solution of Na₂S₂O₃ (50 mL) was added and the organic phase was separated. An aqueous layer was additionally extracted with CH₂Cl₂ and combined organic solutions were washed with the saturated solution of Na₂SO₄ and evaporated. The residue was recrystallized from aqueous EtOH.

5-Bromo-2-methyl-3-nitropyridine N-oxide (**3b**), pale-yellow solid; yield 47%; mp 104–105 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.60 (s, 1H), 7.86 (s, 1H), 2.67 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃): δ 148.5, 145.5, 143.5, 122.9, 116.4, 13.8. HRMS (ESI, *m*/z): calcd for C₆H₅BrN₂O₃ [M + H]⁺: 232.9556; found: 232.9563.

2-*Methyl-3-nitro-5-trifluoromethylpyridine N-oxide* (**3c**), pale-yellow solid; yield 65%; mp 82–83 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.69 (s, 1H), 7.89 (s, 1H), 2.75 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 149.9, 148.8, 139.5, 127.1 (q, ²J_{CF} = 36 Hz), 121.1 (q, ¹J_{CF} = 274 Hz), 116.1, 14.3. HRMS (ESI, *m/z*): calcd for C₇H₅F₃N₂O₃ [M + H]⁺: 223.0325; found: 223.0331.

4.4. General Procedure for the Synthesis of Compounds 4a-g

To a solution of the corresponding 2-methylpyridine **2** or **3** (5 mmol) in toluene (30 mL), aromatic aldehyde (5 mmol) and 50 μ L of piperidine was added. The reaction mixture was stirred under reflux with a Dean–Stark adapter until water separation was completed. The solvent was evaporated and the residue was triturated with 20 mL of cold EtOH. The precipitate was filtered off and air-dried.

(*E*)-2-[(4-*Chlorophenyl*)*vinyl*]-3,5-*dinitropyridine* (4a), yellow solid; yield 78%; mp 204–205 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.58 (s, 1H), 9.05 (s, 1H), 8.30 (d, 1H, *J* = 15.3 Hz), 7.83 (d, 1H, *J* = 15.3 Hz), 7.64 (d, 2H, *J* = 8.4 Hz), 7.45 (d, 2H, *J* = 8.4 Hz). ¹³C NMR (150 MHz, DMSO-d₆): δ 152.0, 147.5, 143.2, 141.9, 140.3, 135.0, 134.0, 130.2, 129.2, 129.1, 121.6. HRMS (ESI, *m/z*): calcd for C₁₃H₈ClN₃O₄ [M + H]⁺: 306.0276; found: 306.0283.

(*E*)-4-(2-(3,5-*Dinitropyridin*-2-*y*]*viny*])-*N*,*N*-*dimethylaniline* (**4b**), dark-violet solid; yield 91%; mp 260 °C (dec.); ¹H NMR (300 MHz, CDCl₃): δ 9.41 (d, 1H, *J* = 2.1 Hz), 8.93 (d, 1H, *J* = 2.1 Hz), 8.28 (d, 1H, *J* = 15.0 Hz), 7.64 (d, 1H, *J* = 15.0 Hz), 7.57 (d, 2H, *J* = 8.8 Hz), 6.77 (d, 2H, *J* = 8.8 Hz), 3.06 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): δ 154.8, 152.4, 147.3, 146.4, 139.5, 131.1, 128.9, 123.2, 114.4, 111.9, 40.1. HRMS (ESI, *m*/*z*): calcd for C₁₅H₁₄N₄O₄ [M + H]⁺: 315.1088; found: 315.1085.

(*E*)-5-*Bromo*-2-(4-*dimethylaminophenyl*)*vinyl*-3-*nitropyridine N*-*oxide* (4c), red-brown solid; yield 73%; mp 217 °C (dec.); ¹H NMR (300 MHz, CDCl₃): δ 8.55 (d, 1H, *J* = 15.9 Hz), 8.49 (s, 1H), 7.64 (s, 1H), 7.49 (d, 2H, *J* = 8.7 Hz), 7.00 (d, 1H, *J* = 15.6 Hz), 6.69 (d, 2H, *J* = 8.7 Hz), 3.05 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 151.8, 147.2, 143.9, 142.8, 141.2, 129.9, 123.8, 123.0, 113.0, 111.9, 107.1, 40.1. HRMS (ESI, *m*/z): calcd for C₁₅H₁₄BrNO₃ [M + H]: 364.0291; found: 364.0292.

(*E*)-2-(2-(1-(4-*Fluorophenyl*)-1*H*-*pyrazol*-4-*yl*)*vinyl*)-3,5-*dinitropyridine* (**4d**), brown solid; yield 62%; mp 255 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.53 (d, 1H, *J* = 2.1 Hz), 9.03 (d, 1H, *J* = 2.1 Hz), 8.30 (d,1H, *J* = 15.3 Hz), 8.19 (s, 1H), 8.06 (s, 1H), 7.70 (m, 3H), 7.20 (m, 2H). HRMS (ESI, *m/z*): calcd for C₁₆H₁₀FN₅O₄ [M + H]⁺: 356.0790; found: 356.0789.

(*E*)-2-(4-*Chlorophenyl*)*vinyl*-3-*nitro*-5-*trifluoromethylpyridine* N-*oxide* (4e), yellow solid; yield 81%; mp 161–162 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.65 (d,1H, *J* = 15.9 Hz), 8.64 (s, 1H), 7.73 (s, 1H), 7.52 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 2H, *J* = 8.4 Hz), 7.17 (d, 1H, *J* = 15.9 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 147.9, 143.6, 142.3, 140.4, 136.7, 134.1, 129.4, 129.3, 125.5 (q, ²J_{CF} = 36 Hz), 121.1 (q, ¹J_{CF} = 273 Hz), 116.0 (d, ³J_{CF} = 3.2 Hz), 112.8. HRMS (ESI, *m/z*): calcd for C₁₄H₈ClF₃N₂O₃ [M + H]⁺: 345.0248; found: 345.0239.

(*E*)-5-*Bromo*-2-(4-*chlorophenyl*)*vinyl*-3-*nitropyridine* N-*oxide* (4f), yellow solid; yield 69%; mp 173–174 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.45 (s, 1H), 8.30 (d, 1H, *J* = 16.1 Hz), 7.60 (s, 1H), 7.41 (d, 2H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.02 (d, 1H, *J* = 16.1 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 147.8, 144.1, 140.3, 140.2, 136.1, 134.4, 129.2, 129.1, 122.7, 115.7, 113.1. HRMS (ESI, *m*/z): calcd for C₁₃H₈BrClN₂O₃ [M + H]⁺: 354.9480; found: 354.9472.

(*E*)-2-(4-*Dimethylaminophenyl*)*vinyl*-3-*nitro*-5-*trifluoromethylpyridine* N-*oxide* (4g), red-brown solid; yield 71%; mp 198-199 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.85 (d, 1H, *J* = 15.6 Hz), 8.58 (s, 1H), 7.68 (s, 1H), 7.52 (d, 2H, *J* = 8.4 Hz), 7.10 (d, 1H, *J* = 15.6 Hz), 6.69 (d, 2H, *J* = 8.4 Hz), 3.06 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): δ 152.2, 146.8, 145.1, 144.4, 140.1, 130.5, 123.4, 122.7 (q, ²J_{CF} = 36 Hz), 121.4 (q, ¹J_{CF} = 273 Hz), 116.3 (q, ³J_{CF} = 3.6 Hz), 111.9, 106.6, 40.0. HRMS (ESI, *m/z*): calcd for C₁₆H₁₄F₃N₃O₃ [M + H]⁺: 354.1060; found: 354.1060.

4.5. General Procedure for the Synthesis of Compounds 4h-k

To a solution of the corresponding pyridine N-oxide (0.5 mmol), CH_2Cl_2 (10 mL) was added PCl_3 (0.13 mL) and the mixture was stirred under reflux for 2 h. After cooling, the reaction was washed with a saturated NaHCO₃ solution, dried over Na₂SO₄ and evaporated.

(*E*)-4-(2-(5-*Bromo-3-nitropyridin-2-yl)vinyl*)-*N*,*N*-*dimethylaniline* (**4h**), dark-brown solid; yield 89%; mp 202–203 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.75 (s, 1H), 8.34 (s, 1H), 8.05 (d, 1H,

J = 15.3 Hz), 7.55 (d, 1H, J = 15.6), 7.53 (d, 2H, J = 8.4), 6.71 (d, 2H, J = 8.4 Hz), 3.04 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 153.8, 151.3, 148.8, 145.5, 142.8, 140.5, 135.0, 129.8, 115.5, 115.5, 112.3, 40.4, 29.7. HRMS (ESI, m/z): calcd for C₁₅H₁₄BrN₃O₂ [M + H]⁺: 348.0342; found: 348.0342.

(E)-2-(4-*Chlorophenyl*)*vinyl*-3-*nitro*-5-*trifluoromethylpyridine* (**4i**), yellow solid; yield 89%; mp 138 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.02 (s, 1H), 8.50 (s, 1H), 8.16 (d, 1H, *J* = 15.6 Hz), 8.77 (d, 1H, *J* = 15.6 Hz), 7.59 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.4 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 152.0, 149.2 (q, ³J_{CF} = 3.6 Hz), 143.0, 140.8, 136.1, 133.9, 130.7 (q, ³J_{CF} = 3.6 Hz), 129.4, 129.3, 124.9 (q, ²J_{CF} = 35 Hz), 120.6. HRMS (ESI, *m/z*): calcd for C₁₄H₈ClF₃N₂O₂ [M + H]⁺: 329.0299; found: 329.0311.

(*E*)-5-*Bromo*-2-(4-*chlorostyryl*)-3-*nitropyridine* (4j), yellow solid; yield 94%; mp 184–185 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.83 (d, 1H, *J* = 1.8 Hz), 8.40 (d, 1H, *J* = 1.8 Hz), 8.02 (d, 1H, *J* = 15.6 Hz), 7.68 (d, 1H, *J* = 15.6 Hz), 7.56 (d, 2H, *J* = 8.4 Hz), 7.38 (d, 2H, *J* = 8.4 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 154.0, 147.4, 143.7, 138.4, 135.5, 135.1, 134.2, 129.2, 129.1, 124.9, 117.6. HRMS (ESI, *m/z*): calcd for C₁₃H₈BrClN₂O₂ [M + H]⁺: 338.9530; found: 338.9533.

(*E*)-*N*,*N*-*Dimethyl*-4-(2-(3-*nitro*-5-*trifluoromethylpyridin*-2-*yl*)*vinyl*)*aniline* (**4k**), brown solid; yield 82%; mp 150–151 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.40 (s, 1H), 8.36 (s, 1H), 8.12 (d, 1H, *J* = 15.3 Hz), 7.56 (d, 1H, *J* = 15.3 Hz), 7.49 (d, 2H, *J* = 8.7 Hz), 6.66 (d, 2H, *J* = 8.7 Hz), 2.99 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 153.4, 151.9, 149.1 (q, ³*J*_{CF} = 4 Hz), 143.3, 141.8, 130.8 (q, ³*J*_{CF} = 4 Hz), 130.3, 122.8 (q, ¹*J*_{CF} = 271 Hz), 123.6, 122.9 (q, ²*J*_{CF} = 34 Hz), 115.0, 112.1, 40.2. HRMS (ESI, *m/z*): calcd for C₁₆H₁₄F₃N₃O₂ [M + H]⁺: 338.1111; found: 338.1120.

4.6. General Procedure for the Synthesis of Compounds 5 and 6

To a solution of compound **2**, **3** or **4** (1 mmol) in anhydrous DMF (5 mL), thiol (1 mmol) and K_2CO_3 (0.138 g, 1 mmol) were added. The reaction mixture was stirred for 1-2 h at 60 °C, poured into H₂O (50 mL), acidified with conc. HCl to pH 3 and extracted with CHCl₃ (3 × 20 mL). The organic phase was dried over Na₂SO₄, evaporated and the residue was purified via column chromatography (SiO₂/CHCl₃) or recrystallized from EtOH.

3-(*Benzylsulfanyl*)-2-*methyl*-5-*nitropyridine* (**5a**), beige solid; yield 70%; mp 79–80 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.06 (d, 1H, *J* = 2.1 Hz), 7.35 (m, 5H), 4.24 (s, 2H, CH₂), 2.65 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃): δ 162.7, 142.8, 140.1, 134.9, 134.8, 128.9, 128.8, 128.0, 127.8, 37.1, 23.4. HRMS (ESI, *m*/*z*): calcd for C₁₃H₁₂N₂O₂S [M + H]⁺: 261.0692; found: 261.0699.

3-(*Benzylsulfanyl*)-5-*bromo-2-methylpyridine* N-oxide (**5b**), grey needles; yield 96%; mp 106–107 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.25 (s, 1H), 7.26-7.32 (m, 5H), 7.24 (s, 1H), 4.14 (s, 2H, SCH₂), 2.49 (s, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 147.3, 137.8, 136.8, 134.9, 128.9, 128.1, 127.7, 116.3, 38.5, 14.5. HRMS (ESI, *m/z*): calcd for C₁₃H₁₂BrNOS [M + H]⁺: 309.9896; found: 309.9896.

5-Bromo-3-(4-chlorophenylsulfanyl)-2-methylpyridine N-oxide (**5c**), brown solid; yield 95%; mp 131–132 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.27 (s, 1H), 7.44 (d, 2H, *J* = 8.4 Hz), 7.38 (d, 2H, *J* = 8.4 Hz), 6.89 (s, 1H), 2.56 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 146.7, 138.1, 137.3, 136.0, 134.8, 130.4, 129.0, 127.7, 116.6, 14.6. HRMS (ESI, *m*/*z*): calcd for C₁₂H₉BrClNOS [M + H]⁺: 329.9350; found: 329.9349.

3-(*Benzylsulfanyl*)-5-*bromo*-2-*methylpyridine* (**5d**), pale-yellow crystals; yield 65%; mp 55 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.33 (s, 1H), 7.58 (s, 1H), 7.31 (m, 5H), 4.09 (s, 2H, SCH₂), 2.48 (s, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 155.5, 146.5, 137.3, 135.6, 134.4, 128.9, 128.8, 127.8, 117.9, 37.8, 22.5. HRMS (ESI, *m/z*): calcd for C₁₃H₁₂BrNS [M + H]⁺: 293.9947; found: 293.9956.

3-(*Benzylsulfanyl*)-2-*methyl*-5-(*trifluoromethyl*)*pyridine* (**5e**), yellow oil; yield 60%; ¹H NMR (300 MHz, CDCl₃): δ 8.53 (s, 1H), 7.64 (s, 1H), 7.31 (s, 5H), 4.14 (s, 2H, SCH₂), 2.61 (s, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 161.0, 142.3 (q, ³J_{CF} = 4 Hz), 135.5, 133.4, 131.7 (q,

 ${}^{3}J_{CF} = 3.5 \text{ Hz}$), 128.9, 128.8, 127.8, 124.7 (q, ${}^{2}J_{CF} = 34 \text{ Hz}$), 123.5 (q, ${}^{1}J_{CF} = 273 \text{ Hz}$), 37.5, 23.2. HRMS (ESI, *m/z*): calcd for C₁₄H₁₂F₃NS [M + H]⁺: 284.0715; found: 284.0719.

3-(*Benzylsulfanyl*)-2-*methyl*-5-(*trifluoromethyl*)*pyridine* N-oxide (**5f**), pale-yellow crystals; yield 52%; mp 85–86 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.33 (s, 1H), 7.29 (m, 5H), 7.22 (s, 1H), 4.15 (s, 2H, SCH₂), 2.57 (s, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 151.8, 137.3, 134.7, 134.1, 128.9, 128.9, 128.1, 126.6 (q, ²J_{CF} = 35 Hz), 121.9 (q, ¹J_{CF} = 273 Hz), 120.1, 38.4, 15.0. HRMS (ESI, *m/z*): calcd for C₁₄H₁₂F₃NOS [M + H]⁺: 300.0664; found: 300.0662.

(*E*)-3-(*Benzylsulfanyl*)-2-((4-chlorophenyl)vinyl)-5-nitropyridine (**5g**), yellow crystals; yield 56%; mp 146–147 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.17 (d, 1H, *J* = 2.1 Hz), 8.28 (d, 1H, *J* = 2.1 Hz), 7.92 (d, 1H, *J* = 15.6 Hz), 7.57 (d, 1H, *J* = 15.6 Hz), 7.53 (d, 2H, *J* = 8.7 Hz), 7.30 (m, 5H), 4.18 (s, 2H, SCH₂). ¹³C NMR (75 MHz, CDCl₃): δ 159.0, 142.2, 142.1, 138.1, 135.5, 135.2, 134.5, 132.4, 132.3, 129.2, 129.2, 129.0, 128.9, 128.1, 122.8, 38.7. HRMS (ESI, *m/z*): calcd for C₂₀H₁₅ClN₂O₂S [M + H]⁺: 383.0616; found: 383.0603.

(*E*)-5-(*Benzylsulfanyl*)-2-((4-chlorophenyl)vinyl)-3-nitropyridine (**6g**), yellow crystals; yield 18%; mp 183–184 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.63 (d, 1H, *J* = 1.8 Hz), 8.06 (d, 1H, *J* = 2.1 Hz), 7.97 (d, 1H, *J* = 15.6 Hz), 7.67 (d, 1H, *J* = 15.6 Hz), 7.56 (d, 2H, *J* = 8.7 Hz), 7.39 (d, 2H, *J* = 8.7 Hz), 7.33 (m, 5H), 4.22 (s, 2H, SCH₂). HRMS (ESI, *m*/*z*): calcd for C₂₀H₁₅ClN₂O₂S [M + H]⁺: 383.0616; found: 383.0621.

2-[(*E*)-(4-Chlorophenyl)vinyl]-3-(isobutylsulfanyl)-5-nitropyridine (**5h**), yellow crystals; yield 62%; mp 139–140 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.16 (d, 1H, *J* = 2.4 Hz), 8.31 (d, 1H, *J* = 2.1 Hz), 7.96 (d, 1H, *J* = 15.3 Hz), 7.63 (d, 1H, *J* = 15.3 Hz), 7.60 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.4 Hz), 2.92 (d, 2H, *J* = 6.9 Hz), 1.99 (m, 1H), 1.14 (d, 6H, *J* = 6.6 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 158.0, 147.0, 142.4, 141.0, 137.9, 135.4, 134.5, 134.3, 129.9, 122.8, 42.3, 28.1, 22.2. HRMS (ESI, *m*/*z*): calcd for $C_{17}H_{17}ClN_2O_2S$ [M + H]⁺: 349.0772; found: 349.0783.

2-[(*E*)-(4-*Chlorophenyl*)*vinyl*]-5-(*isobutylsulfanyl*)-3-*nitropyridine* (**6h**), yellow crystals; yield 31%; mp 106 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.68 (d, 1H, *J* = 1.8 Hz), 8.09 (d, 1H, *J* = 1.8 Hz), 7.97 (d, 1H, *J* = 15.6 Hz), 7.68 (d, 1H, *J* = 15.6 Hz), 7.56 (d, 2H, *J* = 8.4 Hz), 7.38 (d, 2H, *J* = 8.4 Hz), 2.92 (d, 2H, *J* = 6.9 Hz), 1.96 (m, 1H), 1.10 (d, 6H, *J* = 6.6 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 152.0, 145.4, 143.9, 136.8, 135.1, 134.9, 134.6, 130.9, 129.1, 129.0, 121.5, 42.1, 28.3, 22.0. HRMS (ESI, *m/z*): calcd for C₁₇H₁₇ClN₂O₂S [M + H]⁺: 349.0772; found: 349.0764. 2-[(*E*)-2-(4-*Chlorophenyl*)*vinyl*]-3-[(2-*furylmethyl*)*sulfanyl*]-5-*nitropyridine* (**5i**), yellow crystals; yield 56%; mp 156 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.24 (d, 1H, *J* = 1.8 Hz), 8.42 (d, 1H, *J* = 2.1 Hz), 7.95 (d, 1H, *J* = 15.6 Hz), 7.65 (d, 1H, *J* = 15.6 Hz), 7.58 (d, 2H, *J* = 8.4 Hz), 7.40 (d, 2H, *J* = 8.4 Hz), 7.33 (s, 1H), 6.26 (s, 1H), 6.14 (d, 1H, *J* = 3.0 Hz), 4.18 (s, 2H). HRMS (ESI, *m/z*): calcd for C₁₈H₁₃ClN₂O₂S [M + H]⁺: 373.0408; found: 373.0419.

3-[(4-Chlorophenyl)sulfanyl]-2-[(E)-2-(4-chlorophenyl)vinyl]-5-nitropyridine (**5**), yellow solid; yield 67%; mp 172 °C; ¹H NMR (300 MHz, DMSO-d₆): δ 9.26 (s, 1H), 8.22 (s, 1H), 7.98 (d, 1H, *J* = 15.6 Hz), 7.74 (d, 2H, *J* = 8.4 Hz), 7.66 (d, 1H, *J* = 15.6 Hz), 7.52 (br.s, 4H), 7.49 (d, 2H, *J* = 8.4 Hz). HRMS (ESI, *m*/*z*): calcd for C₁₉H₁₂Cl₂N₂O₂S [M + H]⁺: 403.0069; found: 403.0057.

(*E*)-4-(2-(3-((4-Chlorophenyl)sulfanyl)-5-nitropyridin-2-yl)vinyl)-N,N-dimethylaniline (**5k**), darkred solid; yield 83%; mp 175 °C; ¹H NMR (300 MHz, DMSO-d₆): δ 9.21 (s, 1H), 8.20 (s, 1H), 7.96 (d, 1H, *J* = 15.6 Hz), 7.50 (m, 6H), 7.36 (d, 1H, *J* = 15.6 Hz), 6.74 (d, 2H, *J* = 8.4 Hz), 2.99 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): δ 160.1, 151.6, 143.1, 141.3, 141.2, 134.9, 133.4, 133.2, 130.9, 130.1, 129.9, 123.7, 117.0, 111.9, 40.1. HRMS (ESI, *m/z*): calcd for C₂₁H₁₈ClN₃O₂S [M + H]⁺: 412.0881; found: 412.0870.

(*E*)-4-(2-(3-(*Isobutylsulfanyl*)-5-*nitropyridin*-2-*y*)*vinyl*)-*N*,*N*-*dimethylaniline* (**5I**), dark-red solid; yield 84%; mp 165–166 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.14 (d, 1H, *J* = 2.4 Hz), 8.27 (d, 1H, *J* = 2.1 Hz), 8.01 (d, 1H, *J* = 15.3 Hz), 7.58 (d, 2H, *J* = 8.7 Hz), 7.46 (d, 1H, *J* = 15.3 Hz), 6.74 (d, 2H, *J* = 8.7 Hz), 3.06 (s, 6H), 2.89 (d, 2H, *J* = 6.6 Hz), 1.96 (m, 1H), 1.13 (d, 6H, *J* = 6.6 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 159.5, 151.5, 141.4, 141.3, 140.2, 132.5, 130.0, 129.8,

124.1, 117.4, 112.0, 43.0, 40.2, 28.1, 22.2. HRMS (ESI, *m/z*): calcd for C₁₉H₂₃N₃O₂S [M + H]⁺: 358.1584; found: 358.1583.

(*E*)-4-(2-(3-(*Benzylsulfanyl*)-5-*nitropyridin*-2-*yl*)*vinyl*)-*N*,*N*-*dimethylaniline* (**5m**), dark-red solid; yield 88%; mp 188 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.13 (d, 1H, J = 2.1 Hz), 8.20 (d, 1H, J = 1.8 Hz), 7.98 (d, 1H, J = 15.3 Hz), 7.54 (d, 2H, J = 8.7 Hz), 7.43 (d, 1H, J = 15.3 Hz), 7.30 (m, 5H), 6.70 (d, 2H, J = 8.7 Hz), 4.16 (s, 2H), 3.05 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 160.4, 151.5, 142.3, 141.0, 140.5, 135.5, 132.2, 130.6, 129.9, 129.0, 128.8, 127.9, 124.0, 117.4, 112.0, 40.2, 38.5. HRMS (ESI, *m/z*): calcd for C₂₂H₂₁N₃O₂S [M + H]⁺: 392.1427; found: 392.1417.

(*E*)-3-(*Benzylsulfanyl*)-2-(2-(1-(4-*fluorophenyl*)-1*H*-*pyrazol*-4-*yl*)*vinyl*)-5-*nitropyridine* (**5n**), or-ange solid; yield 89%; mp 145–146 °C; ¹H NMR (300 MHz, CDCl₃): δ 9.15 (d, 1H, *J* = 2.1 Hz), 8.26 (d, 1H, *J* = 2.1 Hz), 8.05 (s, 1H), 7.98 (s, 1H), 7.92 (d, 1H, *J* = 15.3 Hz), 7.67 (m, 2H), 7.40 (d, 1H, *J* = 15.3 Hz), 7.30 (m, 5H), 7.18 (m, 2H), 4.18 (s, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 161.4 (d, ¹J_{CF} = 247 Hz), 159.3, 142.1, 141.8, 140.3, 136.0 (d, ⁴J_{CF} = 3 Hz), 135.3, 132.2, 131.5, 129.3, 129.0, 128.9, 128.0, 126.4, 121.9, 121.4, 121.1 (d, ³J_{CF} = 8.5 Hz), 116.5 (d, ²J_{CF} = 23 Hz), 38.6. HRMS (ESI, *m/z*): calcd for C₂₃H₁₇FN₄O₂S [M + H]⁺: 433.1129; found: 433.1123.

(*E*)-3-((*4*-*Chlorophenyl*)*sulfanyl*)-2-(2-(1-(*4*-*fluorophenyl*)-1H-*pyrazol*-4-*yl*)*vinyl*)-5-*nitropyridine* (**50**), orange solid; yield 93%; mp 219 °C; ¹H NMR (300 MHz, DMSO-d₆): δ 9.24 (s, 1H), 8.99 (s, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 7.80 (m, 4H), 7.55 (s, 4H), 7.40 (m, 3H). HRMS (ESI, *m/z*): calcd for C₂₂H₁₄ClFN₄O₂S [M + H]⁺: 453.0583; found: 453.0573.

(*E*)-3-(*Benzylsulfanyl*)-5-*bromo*-2-[(4-chlorophenyl)vinyl]pyridine (**5p**), beige solid, yield 60%; mp 142–143 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.48 (s, 1H), 7.69–7.73 (m, 2H), 7.48–7.56 (m, 3H), 7.25-7.36 (m, 7H), 4.08 (s, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 153.2, 148.4, 141.1, 135.9, 135.1, 134.3, 133.6, 132.5, 128.9, 128.8, 128.7, 128.6, 127.7, 123.7, 118.3, 39.4. HRMS (ESI, *m/z*): calcd for C₂₀H₁₅BrCINS [M + H]⁺: 415.9869; found: 415.9870.

(E)-3-(*Benylsulfanyl*)-5-bromo-2-[(4-(*dimethylamino*)phenyl)vinyl]pyridine N-oxide (**5q**), darkred solid; yield 67%; mp 177 °C; ¹H NMR (300 MHz, CDCl₃): δ 8.49 (d, 1H, *J* = 15.9 Hz), 8.23 (s, 1H), 7.51 (d, 2H, *J* = 8.7 Hz), 7.28 (m, 7H), 6.71 (d, 2H, *J* = 8.7 Hz), 4.14 (s, 2H), 3.03 (s, 6H, NCH₃). ¹³C NMR (75 MHz, CDCl₃): δ 151.2, 144.9, 140.5, 139.0, 135.9, 135.0, 129.2, 129.1, 128.8, 128.4, 127.9, 127.8, 124.8, 114.1, 112.1, 40.3, 39.0. HRMS (ESI, *m/z*): calcd for C₂₂H₂₁BrN₂OS [M + H]⁺: 441.0631; found: 441.0635.

4.7. X-ray Crystallographic Data and Refinement Details

X-ray diffraction data for 5h were collected at 100 K on a Bruker Quest D8 diffractometer (Karlsruhe, Germany) equipped with a Photon III area detector, using graphitemonochromatized Mo K_{α}-radiation and a shutterless φ - and ω -scan technique. The intensity data were integrated by the SAINT program (version 8.04A) [21] and were semi-empirically corrected for absorption and decay using SADABS (2016/2) [22]. X-ray diffraction data for 4a, 4i and 5l were collected at 100 K on a four-circle Rigaku Synergy-S diffractometer (Wroclaw, Poland) equipped with a HyPix6000HE area detector, using monochromatized Cu K_{α}-radiation and a shutterless ω -scan technique. The intensity data were integrated and corrected for absorption and decay by the CrysAlisPro program [23]. All structures were solved by direct methods using SHELXT [24] and refined by the full-matrix least-squares method on F^2 using SHELXL-2018 [25]. Positions of all atoms were found from the electron density difference map. Atoms were refined with individual anisotropic (non-hydrogen atoms) or isotropic (hydrogen atoms) displacement parameters. The Mercury program [26] was used for molecular graphics. Crystal data, data collection and structure refinement details are summarized in Supplementary Materials Table S1. The structures were deposited at the Cambridge Crystallographic Data Center with the reference CCDC numbers 2191010–2191013; they also contain the supplementary crystallographic data. These data can be obtained free of charge from the CCDC via http://www.ccdc.cam.ac.uk/data_request/cif, accessed on 30 August 2022.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/molecules27175692/s1, X-ray data, ¹H and ¹³C NMR spectra. References [19–26] are cited in the supplementary materials.

Author Contributions: Conceptualization, V.V.N. and A.M.S.; methodology, V.V.N. and M.A.B.; investigation, V.V.N. and M.E.M.; resources, M.E.M.; writing—original draft preparation, V.V.N. and M.A.B.; writing—review and editing, A.M.S.; supervision, A.M.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Acknowledgments: In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

- Khan, E. Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes. *ChemistrySelect* 2021, 6, 3041–3064. [CrossRef]
- Yang, S.; Yan, J.; Wang, L.; Guo, X.; Li, S.; Wu, G.; Zuo, R.; Huang, X.; Wang, H.; Wang, L.; et al. Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof. U.S. Patent 20140073796A1, 27 January 2015.
- 3. Jhons, B.A.; Spaltenstein, A. HIV Integrase Inhibitors. U.S. Patent WO 2007/09101 A2, 18 January 2007.
- Romero, D.L.; Morge, R.A.; Biles, C.; Berrios-Pena, N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M. Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem. 1994, 37, 999–1014. [CrossRef] [PubMed]
- Kuduk-Jaworska, J.; Puzsko, A.; Kubiak, M.; Pelczynska, M. Synthesis, structural, phisico-chemical and biological properties of new palladium(II) complexes with 2,6-dimethyl-4-nitropyridine. *J. Inorg. Biochem.* 2004, 98, 1447–1456. [CrossRef] [PubMed]
- Klapötke, T.M.; Stierstorfer, J.; Weyrauther, M.; Witkowski, T.G. Synthesis and Investigation of 2,6-Bis(picrylamino)-3,5-dinitropyridine (PYX) and Its Salts. *Chem.–A Eur. J.* 2016, 22, 8619–8626. [CrossRef] [PubMed]
- Agrawal, J.P.; Prasad, U.S.; Surve, R.N. Synthesis of 1,3-bis(1,2,4-triazol-3-amino)-2,4,6-trinitrobenzene and its thermal and explosive behaviour. *New J. Chem.* 2000, 24, 583–585. [CrossRef]
- 8. Balachari, D.; Trudell, M.L. Synthesis of new dipyridotetraazapentalenes. Tetrahedron Lett. 1997, 38, 8607–8610. [CrossRef]
- 9. Balachari, D.; Stevens, E.D.; Trudell, M.L.; Beardall, D.; Wight, C.A. Synthesis, Thermal Stability and Impact Stability of Novel Tetranitro-Dipyridotetraazapentalene Derivatives. *Propell. Explos. Pyrotech.* **2000**, *25*, 75–80. [CrossRef]
- 10. Kauer, J.C.; Carboni, R.A. Aromatic azapentalenes. III. 1,3a,6,6a-Tetraazapentalenes. J. Am. Chem. Soc. 1967, 89, 2633–2637. [CrossRef]
- Gryl, M.; Seidler, T.; Wojnarska, J.; Stadnicka, K.M.; Matulková, I.; Němec, I.; Němec, P. Co-Crystals of 2-Amino-5-Nitropyridine Barbital with Extreme Birefringence and Large Second Harmonic Generation Effect. *Chem.–A Eur. J.* 2018, 24, 8727–8731. [CrossRef] [PubMed]
- 12. Bastrakov, M.A.; Nikol'Skiy, V.V.; Starosotnikov, A.M.; Fedyanin, I.V.; Shevelev, S.A.; Knyazev, D.A. Reactions of 3-R-5nitropyridines with nucleophiles: Nucleophilic substitution vs conjugate addition. *Tetrahedron* **2019**, *75*, 130659. [CrossRef]
- 13. Frank, R.; Christoph, T.; Lesch, B.; Lee, J. Substituted heterocyclic aza derivatives. WO Patent 2013013817, 31 January 2013.
- 14. Van der Eycken, E.; Jidong, Z.; Kilonda, A.; Compernolle, F.; Toppet, S.; Hoornaert, G.; Van der Auweraer, M.; Jackers, C.; Verbouwe, W.; De Schryver, F.C. Synthesis of (E)-5-(2-arylvinyl)-2-(hetero)arylpyridines, (E)-2-(2-arylvinyl)-5-methoxycarbonylpyridines and (E,E)-2,5-bis(2-arylvinyl)pyridines as polarity and pH probesElectronic supplementary information (ESI). *J. Chem. Soc. Perkin Trans.* **2002**, *2*, 928–937. [CrossRef]
- Iyer, S.; Ramesh, C. Aryl–Pd covalently bonded palladacycles, novel amino and oxime catalysts {di-μ-chlorobis(benzaldehydeoxime-6-C,N)dipalladium(II), di-μ-chlorobis(dimethylbenzylamine-6-C,N)dipalladium(II)} for the Heck reaction. *Tetrahedron Lett.* 2000, 41, 8981–8984. [CrossRef]
- Amatore, C.; Jutand, A. Anionic Pd(0) and Pd(II) Intermediates in Palladium-Catalyzed Heck and Cross-Coupling Reactions. Accounts Chem. Res. 2000, 33, 314–321. [CrossRef] [PubMed]
- Lubisch, W.; Beckenbach, E.; Bopp, S.; Hofmann, H.-P.; Kartal, A.; Kästel, C.; Lindner, T.; Metz-Garrecht, M.; Reeb, J.; Regner, F.; et al. Benzoylalanine-Derived Ketoamides Carrying Vinylbenzyl Amino Residues: Discovery of Potent Water-Soluble Calpain Inhibitors with Oral Bioavailability. J. Med. Chem. 2003, 46, 2404–2412. [CrossRef] [PubMed]

- 18. Lee, D.-H.; Taher, A.; Hossain, S.; Jin, M.-J. An Efficient and General Method for the Heck and Buchwald–Hartwig Coupling Reactions of Aryl Chlorides. *Org. Lett.* **2011**, *13*, 5540–5543. [CrossRef] [PubMed]
- 19. Liu, M.-C.; Lin, T.-S.; Sartorelli, A.C. A One-Pot Synthesis of 3-Nitro-and 3,5-Dinitro-2-Picolines. *Synth. Commun.* **1990**, *20*, 2965–2970. [CrossRef]
- Jones, C.D.; William, R.; Luke, A.; McCoull, W. Aminopyrimidine Derivatives with TIE2 Inhibiting Activity. U.S. Patent 20080194552 A1, 14 August 2008.
- 21. Bruker. APEX-III; Bruker AXS Inc.: Madison, WI, USA, 2019.
- Krause, L.; Herbst-Irmer, R.; Sheldrick, G.M.; Stalke, D. Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination. J. Appl. Crystallogr. 2015, 48, 3–10. [CrossRef]
- 23. CrysAlisPro. Version 1.171.41.106a. In Rigaku Oxford Diffraction; Rigaku Corporation: Oxford, UK, 2021.
- Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. Sect. A Found. Adv. 2015, 71, 3–8. [CrossRef] [PubMed]
- 25. Sheldrick, G.M. Crystal structure refinement with *SHELXL*. *Acta Crystallogr. Sect. C Struct. Chem.* **2015**, *C71*, 3–8. [CrossRef] [PubMed]
- Macrae, C.F.; Sovago, I.; Cottrell, S.J.; Galek, P.T.A.; McCabe, P.; Pidcock, E.; Platings, M.; Shields, G.P.; Stevens, J.S.; Towler, M.; et al. *Mercury* 4.0: From visualization to analysis, design and prediction. *J. Appl. Crystallogr.* 2020, 53, 226–235. [CrossRef] [PubMed]